Companies /Healthcare

Cytokinetics Inc

NASDAQ: CYTK Biotechnology
$71.40
▲ $0.49 (+0.69%) today
Markets closed · 10:16pm ET

Q2 2025 Earnings

Reported Aug 7, 2025, 4:01pm ET · SEC source
$-1.12
Beat +16.12%
EPS · est. $-1.34
$66.8M
Beat +3,131.07%
Revenue · est. $2.1M
+50.1%
Beating market
CYTK vs S&P since report
1 quarter
Consecutive EPS beats

Market Reaction

% change · around the report
−3%0+3%Aug 7Aug 8report 4:01pm ETearnings+0.8%−3.1%
−3%0+3%Aug 7Aug 8earnings+0.8%−3.1%
CYTK −3.1%S&P 500 +0.8%
−3%0+3%Aug 7Aug 8report 4:01pm ETearnings+0.9%−3.1%
−3%0+3%Aug 7Aug 8earnings+0.9%−3.1%
CYTK −3.1%NASDAQ +0.9%
−6%0+6%+12%Aug 6Aug 15report 4:01pm ETearnings+1.7%+10.3%
−6%0+6%+12%Aug 6Aug 15earnings+1.7%+10.3%
CYTK +10.3%S&P 500 +1.7%
−6%0+6%+12%Aug 6Aug 15report 4:01pm ETearnings+1.4%+10.3%
−6%0+6%+12%Aug 6Aug 15earnings+1.4%+10.3%
CYTK +10.3%NASDAQ +1.4%
−3.23%
Day of report
−2.58%
Next session
+13.37%
One week
+52.45%
30 days

S&P 500 over the same 30 days: +2.36%.

Did CYTK Beat Earnings? Q2 2025 Results

Cytokinetics delivered a sharply better-than-expected second quarter, with revenue of $66.77 million demolishing the $2.07 million consensus estimate by 3,131.07% and surging 26,714.9% from just $249,000 a year ago, as a $52.40 million recognition from its Bayer license and collaboration agreement for aficamten in Japan, combined with $11.70 million in clinical milestone payments, reshaped the top line almost overnight. The loss per share of $1.12 also came in well ahead of the $1.34 consensus estimate, a 16.12% beat, though the company still posted a net loss of $134.37 million as R&D spending climbed to $112.55 million and G&A costs reached $65.72 million, both reflecting aggressive commercial readiness investments ahead of aficamten's December 26, 2025 PDUFA date. Management held its full-year operating expense guidance steady at $670 million to $710 million, signaling confidence in its spending trajectory as a late-cycle FDA meeting approaches in September and MAPLE-HCM primary results head to the ESC Congress in August.

Key Takeaways
  • Recognition of $52.4 million from Bayer license and collaboration agreement for aficamten in Japan
  • $11.7 million in clinical milestones from non-obstructive and obstructive HCM trials in Japan
  • $75 million drawn from Tranche 4 of Royalty Pharma Multi Tranche Term Loan

“Following solid progress in the first half of the year, we are looking forward to several key corporate milestones. Our primary focus remains on preparations for the potential FDA approval of aficamten in late December and subsequent commercial launch in early 2026.”

Cytokinetics CEO, on the earnings call

Forward Guidance & Outlook

Cytokinetics maintained its full-year 2025 GAAP operating expense guidance of $670 million to $710 million, including $110 million to $120 million in non-cash stock-based compensation. The anticipated year-over-year increase in operating expense reflects investments toward commercial readiness for the potential approval and launch of aficamten for obstructive HCM. Key upcoming milestones include: the FDA late-cycle meeting for aficamten in September 2025, the PDUFA target action date of December 26, 2025, a potential EMA decision in 1H 2026, MAPLE-HCM primary results at ESC Congress in August 2025, ACACIA-HCM primary cohort topline results in 1H 2026, completion of CEDAR-HCM adolescent cohort enrollment in 2H 2025, and continued COMET-HF enrollment through 2025 targeting completion in late 2026.

CYTK YoY Financials

Q2 2025 vs Q2 2024 · SEC filings Q2 2024 Q2 2025
$-120,000,000$-60,000,000$0$60.0M$249,000$66.8MRevenue$-97,521,427$-111,506,000Operating Income$-126,477,786$-134,370,000Net Income
$-120,000,000$-60,000,000$0$60.0MRevenueOperating IncomeNet Income

CYTK Revenue by Segment

Net Product Revenue (MYQORZO)
License and Milestone Revenues
Collaboration Revenues

Figures from SEC filings and company reports. Not investment advice.